Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: rogermci® who wrote (104)	2/3/2000 8:41:00 PM
From: Tom Hua	Read Replies (2) \| Respond to of 286

Roger, I added at 63 and change. You may want to consider selling some MKTY as well, same price as HYSQ. I did both today. Regards, Tom

To: rogermci® who wrote (104)	2/3/2000 10:03:00 PM
From: Richaaard	Read Replies (2) \| Respond to of 286

All this for Rathmann? Rathman brings instant validation to HYSQ and their work. I think a lot of people were intrigued but not sure whether they should invest prior to his arrival. There is also the idea that he would not have taken this job unless he saw HYSQ as one of the potential leaders. He certainly wouldn't have risked riding off into the sunset on a loser. Also, keep in mind that he probably studied the patent lawsuit against AFFX. A man in his position at his age would not have taken this job if he felt there was any chance of getting embarrassed in court on this. I think it's save to assume that he believes that HYSQ will prevail on the patent issue. How many points could that add to the HYSQ stock price?